January, come a year after the drugmaker slashed 7 percent of the workforce at Kite Pharma, its cell therapy business.

The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...

The FDA has cleared the research organization's investigational new drug application, allowing it to start clinical tests of the experimental treatment DT2-SCT.

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

The bill would establish the right of cancer patients to access advanced care, including precision medicine and genomic testing, in their communities.

The agency had previously recommended against marketing authorization for the Alzheimer's disease but reconsidered after a review.

The panels assess genes with strong disease links and clinical management guidelines, but the firm offers limited-evidence genes as an add-on option.

The pharmaceutical distributor has launched InspiroGene, a business unit offering logistics and other support for ...

This is the first gene therapy for AADC deficiency to receive US regulatory approval and the first that can be administered directly to the brain.

A 31-year-old woman with stage IV breast cancer learns a test ordered more than a year before her diagnosis detected a TP53 ...

NEW YORK – Syros Pharmaceuticals said on Tuesday that its retinoic acid receptor-alpha agonist tamibarotene, which it was testing in combination with azacitidine in patients newly diagnosed with ...